Article: High-affinity peptide-based anticancer vaccination to overcome resistance to immunostimulatory antibodies

We tested how to eradicate long-established immunogenic tumors that were resistant to the monoclonal antibody-mediated blockade of PD-L1 (PD-1 ligand 1) and cytotoxic T lymphocyte-associated protein 4 (CTLA4). Bacterial vaccination with a tumor-specific peptide exhibiting a high affinity for its respective MHC molecule consistently eradicated tumors when combined with a PD-L1 blocking antibody. This approach can be translated to the clinic by combining cancer cell whole-exome sequencing with algorithms to identify mutant peptides with high peptide-MHC binding affinity.

Citing Articles

Immunotherapy for cancer in the central nervous system: Current and future directions.

Binder D, Davis A, Wainwright D Oncoimmunology. 2016; 5(2):e1082027.

PMID: 27057463 PMC: 4801467. DOI: 10.1080/2162402X.2015.1082027.

Classification of current anticancer immunotherapies.

Galluzzi L, Vacchelli E, Bravo-San Pedro J, Buque A, Senovilla L, Baracco E Oncotarget. 2014; 5(24):12472-508.

PMID: 25537519 PMC: 4350348. DOI: 10.18632/oncotarget.2998.

References

1.

Hodi F, ODay S, Mcdermott D, Weber R, Sosman J, Haanen J . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-23. PMC: 3549297. DOI: 10.1056/NEJMoa1003466. View

2.

Taube J, Anders R, Young G, Xu H, Sharma R, McMiller T . Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012; 4(127):127ra37. PMC: 3568523. DOI: 10.1126/scitranslmed.3003689. View

3.

Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, Mcdermott D . Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26):2443-54. PMC: 3544539. DOI: 10.1056/NEJMoa1200690. View

4.

Wortzel R, Philipps C, Schreiber H . Multiple tumour-specific antigens expressed on a single tumour cell. Nature. 1983; 304(5922):165-7. DOI: 10.1038/304165a0. View

5.

van Rooij N, van Buuren M, Philips D, Velds A, Toebes M, Heemskerk B . Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol. 2013; 31(32):e439-42. PMC: 3836220. DOI: 10.1200/JCO.2012.47.7521. View

6.

Wolchok J, Kluger H, Callahan M, Postow M, Rizvi N, Lesokhin A . Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013; 369(2):122-33. PMC: 5698004. DOI: 10.1056/NEJMoa1302369. View

7.

Engels B, Engelhard V, Sidney J, Sette A, Binder D, Liu R . Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity. Cancer Cell. 2013; 23(4):516-26. PMC: 3658176. DOI: 10.1016/j.ccr.2013.03.018. View

8.

Kvistborg P, Shu C, Heemskerk B, Fankhauser M, Thrue C, Toebes M . TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients. Oncoimmunology. 2012; 1(4):409-418. PMC: 3382882. DOI: 10.4161/onci.18851. View

9.

Binder D, Engels B, Arina A, Yu P, Slauch J, Fu Y . Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer. Cancer Immunol Res. 2014; 1(2):123-33. PMC: 3895468. DOI: 10.1158/2326-6066.CIR-13-0058. View

10.

Robbins P, Lu Y, El-Gamil M, Li Y, Gross C, Gartner J . Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med. 2013; 19(6):747-52. PMC: 3757932. DOI: 10.1038/nm.3161. View

High-affinity Peptide-based Anticancer Vaccination to Overcome Resistance to Immunostimulatory Antibodies